Introduction:

Invasive fungal infections (IFI) are a significant cause of morbidity and mortality in recipients of allogeneic hematopoietic stem cell transplantation (Alo-HSCT). This study describes the experience of a single center in Uruguay with the use of voriconazole as prophylaxis during the first 70 days post Alo-HSCT.

Objectives:

To describe the prevalence of IFI, the tolerance to voriconazole, and the associated adverse effects in Alo-HSCT recipients.

Method:

A prospective observational study was conducted at the British Hospital of Montevideo, Uruguay, between January 5, 2022, and June 5, 2024. The patient population that received voriconazole prophylaxis was evaluated.

Results:

Out of 19 patients, 17 met the inclusion criteria. The median age was 57 years, and 70.6% were male. No patients developed IFI. All showed good tolerance to voriconazole without significant adverse events. Therapeutic levels were adequate in 76.5% of cases, while 23.5% presented subtherapeutic levels that were successfully adjusted.

Conclusions:

The use of voriconazole as prophylaxis in Alo-HSCT recipients demonstrated good tolerance and effectiveness in preventing IFI in our center.

        · abstract in Spanish | Portuguese     · text in Spanish     · Spanish ( pdf )